

Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/MD860936D4C7EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: MD860936D4C7EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Moderate and Severe Chronic Kidney Disease Understanding

Moderate and Severe Chronic Kidney Disease: Overview

Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Kidney function is measured by how well the kidneys clean the blood. The glomerular filtration rate (GFR) is a good way to find out the patient's stage of kidney disease. The stages range from very mild (stage 1) to kidney failure (stage 5). Stage 3A Moderate CKD (GFR = 45-59 mL/min), Stage 3B Moderate CKD (GFR = 30-44 mL/min), and Stage 4 Severe CKD (GFR = 15-29 mL/min). Determining the cause of CKD distinguishes whether the patient has a systemic condition or a localized condition in the kidney such as glomerular disease because this functionality affects

management.

“Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate and Severe Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Moderate and Severe Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Moderate and Severe Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate and Severe Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.

Moderate and Severe Chronic Kidney Disease Emerging Drugs Chapters

This segment of the Moderate and Severe Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate and Severe Chronic Kidney Disease Emerging Drugs

KBP-5074: KBP Biosciences

KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs. KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney

Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated.

ELIXCYTE: UnicoCell Biomed

ELIXCYTE is an allogeneic adipose stem cell product and is currently undergoing two human clinical trials. For chronic kidney disease (CKD) treatment (NCT02933827), the phase-II clinical trial is ongoing.

Further product details are provided in the report.....

Moderate and Severe Chronic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Moderate and Severe Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Moderate and Severe Chronic Kidney Disease

There are approx. 4+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase II include, KBP Bioscience.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Moderate and Severe Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate and Severe Chronic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate and Severe Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate and Severe Chronic Kidney Disease drugs.

Moderate and Severe Chronic Kidney Disease Report Insights

- Moderate and Severe Chronic Kidney Disease Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Moderate and Severe Chronic Kidney Disease Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Moderate and Severe Chronic Kidney

Disease drugs?

How many Moderate and Severe Chronic Kidney Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate and Severe Chronic Kidney Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate and Severe Chronic Kidney Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Moderate and Severe Chronic Kidney Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

KBP Bioscience

UnicoCell Biomed

Key Products

KBP-5074

ELIXCYTE

Contents

Introduction

Executive Summary

Moderate and Severe Chronic Kidney Disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Moderate and Severe Chronic Kidney Disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Moderate and Severe Chronic Kidney Disease companies' collaborations, Licensing, Acquisition -Deal Value Trends

Moderate and Severe Chronic Kidney Disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

KBP-5074: KBP Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Moderate and Severe Chronic Kidney Disease Key Companies

Moderate and Severe Chronic Kidney Disease Key Products

Moderate and Severe Chronic Kidney Disease- Unmet Needs

Moderate and Severe Chronic Kidney Disease- Market Drivers and Barriers

Moderate and Severe Chronic Kidney Disease- Future Perspectives and Conclusion

Moderate and Severe Chronic Kidney Disease Analyst Views

Moderate and Severe Chronic Kidney Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Moderate and Severe Chronic Kidney Disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Moderate and Severe Chronic Kidney Disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/MD860936D4C7EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MD860936D4C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970